Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8907 results

  1. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

  2. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

  3. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

  4. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

  5. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

  6. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

  7. AposHealth for knee osteoarthritis (MIB284)

    This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671

  8. Artificial intelligence for analysing chest X-ray images (MIB292)

    This medtech innovation briefing has been updated and replaced by HealthTech guidance 696

  9. Kurin Lock for blood culture collection (MIB297)

    This medtech innovation briefing (MIB) has been replaced by NICE healthtech guidance 715.

  10. Prontosan for acute and chronic wounds (MIB220)

    This advice has been updated and replaced by NICE healthtech guidance 616.

  11. Synergo for non-muscle-invasive bladder cancer (MIB226)

    This advice has been updated and replaced by NICE healthtech guidance 601.

  12. AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)

    This advice has been updated and replaced by NICE healthtech guidance 607.